Related Experiment Video
Updated: Jan 7, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease
Ying Xia1,2, Matthew W Dean2, Pierrick Bourgeat1
1The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.
Introduction:
The cholinergic basal forebrain system, particularly the nucleus basalis of Meynert (Ch4), is selectively vulnerable to amyloid beta (Aβ) and tau in Alzheimer's disease (AD). Their interplay may be a critical driver of AD progression, but remains poorly understood.
Methods:
Data from 779 older individuals in the Australian Imaging, Biomarker, and Lifestyle study were analyzed, all of whom underwent 18F-NAV4694 Aβ and 18F-MK6240 tau positron emission tomography and magnetic resonance imaging.
Results:
The co-occurrence of Aβ and mesial-temporal (MTL) tau pathologies was associated with reduced Ch4 volumes in cognitively unimpaired individuals. MTL tau burden was associated with Ch4 volumes exclusively in cognitively unimpaired individuals with established Aβ pathology, which was not observed for the hippocampus. This association persists in individuals with mild cognitive impairment, but was not apparent in AD dementia.
Discussion:
Findings underscore early Ch4 degeneration associated with Aβ and tau pathologies, supporting potential cognitive benefits of cholinergic therapies in early disease stages.
Highlights:
Early-stage tau pathology in the mesial-temporal (MTL) region was assessed using 18F-MK6240 positron emission tomography. Co-occurring amyloid beta and MTL tau was linked to reduced nucleus basalis of Meynert (Ch4) volume in cognitively unimpaired individuals. Ch4 volume was associated with MTL tau burden exclusively in preclinical Alzheimer's disease (AD). No comparable association was observed between MTL tau and hippocampal volume. The MTL tau-Ch4 association persisted into the prodromal stage of AD.
Insights
Amyloid beta and tau pathologies are linked to early degeneration of the nucleus basalis of Meynert (Ch4) in preclinical Alzheimer's disease (AD). This highlights potential benefits of cholinergic therapies in early AD stages.
Area of Science:
- Neuroscience
- Neuropathology
- Biomarker Research
Background:
- The nucleus basalis of Meynert (Ch4) is vulnerable in Alzheimer's disease (AD).
- Amyloid beta (Aβ) and tau pathology interplay in AD progression is poorly understood.
Purpose of the Study:
- Investigate the association between Aβ, tau, and Ch4 volume.
- Determine if this association differs across cognitive states.
Main Methods:
- Analyzed data from 779 older adults using PET imaging for Aβ and tau.
- Utilized MRI to assess Ch4 and hippocampal volumes.
Main Results:
- Co-occurring Aβ and mesial-temporal (MTL) tau linked to reduced Ch4 volume in cognitively unimpaired individuals.
- MTL tau-Ch4 association found in preclinical AD, persisting into mild cognitive impairment, but not in AD dementia.
- No similar association observed between MTL tau and hippocampal volume.
Conclusions:
- Early Ch4 degeneration is associated with Aβ and tau pathologies.
- Findings support cholinergic therapies for early AD stages.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment
01:30Dementia
The progression of dementia is generally gradual....